Exxonmobil Investment Management Inc. TX decreased its position in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 1.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 26,121 shares of the company’s stock after selling 385 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Laboratory Corp. of America Holdings were worth $3,591,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LH. Oppenheimer & Co. Inc. boosted its position in shares of Laboratory Corp. of America Holdings by 0.4% in the second quarter. Oppenheimer & Co. Inc. now owns 2,396 shares of the company’s stock worth $312,000 after buying an additional 9 shares during the period. Concert Wealth Management Inc. boosted its position in shares of Laboratory Corp. of America Holdings by 0.4% in the second quarter. Concert Wealth Management Inc. now owns 2,393 shares of the company’s stock worth $313,000 after buying an additional 10 shares during the period. Cleararc Capital Inc. boosted its position in shares of Laboratory Corp. of America Holdings by 0.8% in the second quarter. Cleararc Capital Inc. now owns 2,494 shares of the company’s stock worth $325,000 after buying an additional 20 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its position in shares of Laboratory Corp. of America Holdings by 0.6% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 3,905 shares of the company’s stock worth $509,000 after buying an additional 22 shares during the period. Finally, Eaton Vance Management boosted its position in shares of Laboratory Corp. of America Holdings by 0.6% in the second quarter. Eaton Vance Management now owns 3,733 shares of the company’s stock worth $486,000 after buying an additional 23 shares during the period. 91.24% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Laboratory Corp. of America Holdings (NYSE:LH)

Shares of Laboratory Corp. of America Holdings (NYSE:LH) traded down 1.41% during trading on Monday, reaching $125.71. 740,019 shares of the company were exchanged. The company’s 50-day moving average is $129.92 and its 200 day moving average is $132.91. Laboratory Corp. of America Holdings has a 1-year low of $97.79 and a 1-year high of $141.32. The firm has a market capitalization of $12.95 billion, a PE ratio of 19.93 and a beta of 0.96.

Laboratory Corp. of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 26th. The company reported $2.25 EPS for the quarter, missing the consensus estimate of $2.29 by $0.04. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.38 billion. Laboratory Corp. of America Holdings had a net margin of 6.85% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 earnings per share. Equities research analysts expect that Laboratory Corp. of America Holdings will post $8.78 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Exxonmobil Investment Management Inc. TX Sells 385 Shares of Laboratory Corp. of America Holdings (LH)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/28/exxonmobil-investment-management-inc-tx-sells-385-shares-of-laboratory-corp-of-america-holdings-lh.html.

Several research firms recently issued reports on LH. Canaccord Genuity set a $140.00 target price on Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a research note on Sunday, October 30th. Zacks Investment Research cut Laboratory Corp. of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, August 19th. KeyCorp raised their target price on Laboratory Corp. of America Holdings from $143.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 16th. Mizuho raised their target price on Laboratory Corp. of America Holdings from $132.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, September 15th. Finally, Citigroup Inc. began coverage on Laboratory Corp. of America Holdings in a research note on Friday, September 9th. They issued a “neutral” rating and a $156.00 target price on the stock. They noted that the move was a valuation call. Eight investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $143.13.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Receive News & Stock Ratings for Laboratory Corp. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America Holdings and related stocks with our FREE daily email newsletter.